OpenAI has acquired Orchestra Bio, a startup that builds AI agents to help pharmaceutical teams run drug-development programs, the company announced on Tuesday, Oct. 20, 2026. Orchestra's team and technology are being combined with Rosalind, OpenAI's AI models and tools for life-sciences research. Financial terms were not disclosed, Axios and TechCrunch reported.
What Orchestra does
Scientists and program leaders hand off monitoring and tracking of studies to Orchestra's agents, OpenAI said. Its example: if a manufacturing batch fails and threatens to delay a clinical trial, the agents work out which activities and timelines are affected, gather the relevant information and compare ways to respond, while people make the final call. TechCrunch said the agents also help with tracking finances and clinical-trial scheduling.
Orchestra was founded in San Francisco in 2022 by CEO Ashoka Rajendra and had raised about $20 million from backers including Andreessen Horowitz, 8VC and Insight, according to SiliconANGLE and TechCrunch. OpenAI gave no timeline for when Orchestra's agents will appear in its products.
The bigger race
GPT-Rosalind launched in April as a reasoning model for biology and drug discovery, and Rosalind Workbench connects it to lab tools and data; OpenAI names Novo Nordisk and Moderna as partners. Axios framed the deal as part of a push by OpenAI and Anthropic into science beyond coding and cybersecurity. It follows OpenAI's latest fundraising push (see our story) and Anthropic's IPO filing details (see our story).